{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T06:35:08Z","timestamp":1794378908560,"version":"4.9.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Merck Sharp & Dohme LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>In phase 3 trials (COUGH-1\/COUGH-2), gefapixant 45\u00a0mg twice daily significantly reduced 24-h cough frequency vs placebo in refractory or unexplained chronic cough (RCC or UCC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Here, the efficacy of gefapixant 45\u00a0mg vs placebo was evaluated across COUGH-1\/COUGH-2 in predefined subgroups based on sex, region, age, cough duration, cough severity, cough frequency, and diagnosis (RCC, UCC). Awake cough frequency reductions at Week 12 and LCQ response rates (i.e.,\u2009\u2265\u00a01.3-point improvement) at Week 24 were assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 1360 participants analyzed, gefapixant 45\u00a0mg resulted in consistent awake cough frequency reductions overall and across predefined subgroups at Week 12. Gefapixant also resulted in improved LCQ scores across subgroups at Week 24;\u2009\u2265\u00a070% of participants in each subgroup treated with gefapixant 45\u00a0mg had an LCQ response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These data suggest gefapixant 45\u00a0mg provides consistent objective and subjective efficacy across subgroups of individuals with RCC or UCC.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s00408-022-00553-y","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T18:33:26Z","timestamp":1659119606000},"page":"423-429","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups"],"prefix":"10.1007","volume":"200","author":[{"given":"Jaclyn A.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surinder S.","family":"Birring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter V.","family":"Dicpinigaitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorcan P.","family":"McGarvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyn H.","family":"Morice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian D.","family":"Pavord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Satia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Iskold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"La Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Martin Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Schelfhout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Muccino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,27]]},"reference":[{"key":"553_CR1","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00408-015-9701-2","volume":"193","author":"SA Chamberlain","year":"2015","unstructured":"Chamberlain SA, Garrod R, Douiri A et al (2015) The impact of chronic cough: a cross-sectional European survey. Lung 193:401\u2013408","journal-title":"Lung"},{"key":"553_CR2","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.chest.2017.05.038","volume":"152","author":"Y \u00c7olak","year":"2017","unstructured":"\u00c7olak Y, Nordestgaard BG, Laursen LC et al (2017) Risk factors for chronic cough among 14,669 individuals from the general population. Chest 152:563\u2013573","journal-title":"Chest"},{"key":"553_CR3","first-page":"00160","volume":"7","author":"I Satia","year":"2021","unstructured":"Satia I, Mayhew AJ, Sohel N et al (2021) Prevalence, incidence and characteristics of chronic cough among adults from the Canadian Longitudinal Study on Aging. ERJ Open Res 7:00160\u201302021","journal-title":"ERJ Open Res"},{"key":"553_CR4","doi-asserted-by":"publisher","first-page":"1901136","DOI":"10.1183\/13993003.01136-2019","volume":"55","author":"AH Morice","year":"2020","unstructured":"Morice AH, Millqvist E, Bieksiene K et al (2020) ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J 55:1901136","journal-title":"Eur Respir J"},{"issue":"1 suppl","key":"553_CR5","doi-asserted-by":"publisher","first-page":"1S","DOI":"10.1378\/chest.129.1_suppl.1S","volume":"129","author":"RS Irwin","year":"2006","unstructured":"Irwin RS, Baumann MH, Bolser DC et al (2006) Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest 129(1 suppl):1S\u201323S","journal-title":"Chest"},{"key":"553_CR6","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1080\/14656566.2020.1751816","volume":"21","author":"W-J Song","year":"2020","unstructured":"Song W-J, Chung KF (2020) Pharmacotherapeutic options for chronic refractory cough. Expert Opin Pharmacother 21:1345\u20131358","journal-title":"Expert Opin Pharmacother"},{"key":"553_CR7","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/S0140-6736(12)60776-4","volume":"380","author":"NM Ryan","year":"2012","unstructured":"Ryan NM, Birring SS, Gibson PG (2012) Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet 380:1583\u20131589","journal-title":"Lancet"},{"key":"553_CR8","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1177\/1479972318755722","volume":"15","author":"L Slovarp","year":"2018","unstructured":"Slovarp L, Loomis BK, Glaspey A (2018) Assessing referral and practice patterns of patients with chronic cough referred for behavioral cough suppression therapy. Chron Respir Dis 15:296\u2013305","journal-title":"Chron Respir Dis"},{"key":"553_CR9","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1111\/bph.14677","volume":"176","author":"D Richards","year":"2019","unstructured":"Richards D, Gever JR, Ford AP et al (2019) Action of MK-7264 (gefapixant) at human P2X3 and P2X2\/3 receptors and in vivo efficacy in models of sensitisation. Br J Pharmacol 176:2279\u20132291","journal-title":"Br J Pharmacol"},{"key":"553_CR10","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/S0140-6736(21)02348-5","volume":"399","author":"LP McGarvey","year":"2022","unstructured":"McGarvey LP, Birring SS, Morice AH et al (2022) Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. Lancet 399:909\u2013923","journal-title":"Lancet"},{"key":"553_CR11","doi-asserted-by":"publisher","first-page":"00284","DOI":"10.1183\/23120541.00284-2020","volume":"6","author":"DR Muccino","year":"2020","unstructured":"Muccino DR, Morice AH, Birring SS et al (2020) Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough. ERJ Open Res 6:00284\u201302020","journal-title":"ERJ Open Res"},{"key":"553_CR12","doi-asserted-by":"publisher","first-page":"175346662110497","DOI":"10.1177\/17534666211049743","volume":"15","author":"A Martin Nguyen","year":"2021","unstructured":"Martin Nguyen A, Bacci ED, Vernon M et al (2021) Validation of a visual analog scale for assessing cough severity in patients with chronic cough. Ther Adv Respir Dis 15:17534666211049744","journal-title":"Ther Adv Respir Dis"},{"key":"553_CR13","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/thx.2006.067413","volume":"62","author":"SC Decalmer","year":"2007","unstructured":"Decalmer SC, Webster D, Kelsall AA et al (2007) Chronic cough: how do cough reflex sensitivity and subjective assessments correlate with objective cough counts during ambulatory monitoring? Thorax 62:329\u2013334","journal-title":"Thorax"},{"key":"553_CR14","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1378\/chest.10-0438","volume":"139","author":"A Kelsall","year":"2011","unstructured":"Kelsall A, Houghton LA, Jones H et al (2011) A novel approach to studying the relationship between subjective and objective measures of cough. Chest 139:569\u2013575","journal-title":"Chest"},{"issue":"1","key":"553_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1745-9974-5-5","volume":"5","author":"M Vernon","year":"2009","unstructured":"Vernon M, Leidy NK, Nacson A et al (2009) Measuring cough severity: perspectives from the literature and from patients with chronic cough. Cough 5(1):5","journal-title":"Cough"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-022-00553-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00408-022-00553-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-022-00553-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T04:02:06Z","timestamp":1700884926000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00408-022-00553-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,27]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["553"],"URL":"https:\/\/doi.org\/10.1007\/s00408-022-00553-y","relation":{},"ISSN":["0341-2040","1432-1750"],"issn-type":[{"value":"0341-2040","type":"print"},{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,27]]},"assertion":[{"value":"16 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JAS has received personal fees from Bayer, Bellus Healthcare, Boehringer Ingelheim, GlaxoSmithKline, Menlo, NeRRe Pharmaceuticals, and Shionogi; nonfinancial support from Vitalograph; grant support and personal fees related to the submitted work from Afferent Pharmaceuticals\/Merck & Co., Inc.; and grant support from Bayer, Bellus, GlaxoSmithKline, Menlo, and NeRRe Pharmaceuticals. The VitaloJAK algorithm is owned by Manchester University NHS Foundation Trust (MFT) and licensed to Vitalograph Ltd; MFT receives royalties from Vitalograph that may be shared with the department in which JAS works. JAS is also funded by the NIHR Manchester Biomedical Research Centre and a Wellcome Investigator Award and is an NIHR Senior Investigator. SSB has received advisory board\/consultancy fees from Bayer, Menlo, Merck & Co., Inc., Patara, Pfizer, and Sanofi; speaker fees from Roche; and grant support from Boehringer Ingelheim and Merck & Co., Inc. PVD has received advisory board\/consultancy fees from Bayer HealthCare Pharmaceuticals, Bellus Health Inc, Chiesi, Merck & Co., Inc., and Shionogi. PVD is editor-in-chief of <i>Lung.<\/i> LPM has received advisory board\/consultancy fees from Applied Clinical Intelligence, Bayer, Bellus Health, Bionorica, Chiesi, Merck & Co., Inc., Nocion Therapeutics, and Shionogi. AHM has received consulting fees from Bayer, Bellus, Boehringer Ingelheim, Merck & Co., Inc., Pfizer, Proctor & Gamble, and Shionogi; lecture fees from AstraZeneca and Boehringer Ingelheim; and grant support from Afferent, Infirst, Merck & Co., Inc., and Proctor & Gamble. IDP has received personal fees from Aerocrine, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Genentech, GlaxoSmithKline, Knopp, Novartis, Regeneron, Sanofi, and Teva; and grant support from NIHR. IS has received personal fees from educational talks for general practitioners from AstraZeneca and GlaxoSmithKline; grants and personal fees from Merck Canada; consulting fees from Genentech; a European Respiratory Society Respire 3 Marie Curie Fellowship; and an E.J. Moran Campbell Early Career Award from the Department of Medicine, McMaster University (outside the submitted work). SG, BI, CLR, QL, AMN, JS, and DM are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ USA, who may own stock and\/or hold stock options in the Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The COUGH-1\/COUGH-2 trials were performed in accordance with applicable federal regulations. All sites received approval from institutional review boards or independent ethics committees.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"For the COUGH-1\/COUGH-2 trials, all patients provided written informed consent before enrollment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}